The Use of Teicoplanin in the Treatment of Septicaemia Caused by Coagulase-Negative Staphylococci - A Randomized Study Comparing Bolus Injection With Infused and/or Line-Locked Teicoplanin
- Compare the response and cure rate of coagulase-negative staphylococcal septicemia in
patients receiving chemotherapy through a central venous catheter treated with 2
different schedules of teicoplanin.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
participating center and number of central venous catheter lumens (1 vs 2). Patients are
randomized to one of two treatment arms.
- Arm I: Patients receive teicoplanin IV bolus every 12 hours for 3 doses and then once
daily for 5 doses (total of 7 days).
- Arm II: Patients receive teicoplanin IV over 2 hours and/or by antibiotic lock every 12
hours for 3 doses and then once daily for 5 doses (total of 7 days).
PROJECTED ACCRUAL: Approximately 490-1,360 patients will be accrued for this study within
Allocation: Randomized, Primary Purpose: Supportive Care
Barry Pizer, MD
Royal Liverpool Children's Hospital, Alder Hey
United States: Federal Government